查看文章

Rituximab (RTX) administration in autoimmune diseases (AID) is associated with severe infectious events (SIE). Frequency of SIE and immune reconstitution (B cells, T cells, and immunoglobulins) after RTX have not yet been comprehensively assessed in a prospective study in patients with various AID.

To explore the impact of RTX on immune system in patients with AID including kinetic evolution of biological parameters, and to estimate the rates of hypogammaglobulinemia (HG), severe infectious events (SIE) and immunoglobulins replacement therapy (IgRT).

Patients treated by RTX for AID were included in a prospective study (planned enrollment of 200 patients between May 2019 and May 2022, clinical trial number: NCT03778840). Clinical and biological parameters were recorded at baseline and then every 3 months for one year (M3, M6, M9 and M12). The influence of …